GSK Advances New Phase 3 Trial in Hard-to-Treat Ovarian Cancer: What Investors Should Watch
GlaxoSmithKline (GSK) announced an update on their ongoing clinical study.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
GSK Targets Tough Ovarian Cancer With New Phase 3 Drug Study
The phase 3 study “A Randomized, Open-label, Multicenter, Phase 3 Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer” will test a new GSK drug in women whose cancer no longer responds to platinum therapy. It aims to show if GSK5733584 works better and is safer than current chemotherapy, a key step for future approvals and sales in a high-need cancer setting.
The trial compares GSK5733584, an experimental cancer drug from GlaxoSmithKline, against standard chemotherapy options. These include paclitaxel, pegylated liposomal doxorubicin, topotecan, or gemcitabine, which are widely used but often have limited benefit in platinum-resistant ovarian cancer.
The study is interventional and randomized, meaning participants are assigned by chance to either GSK5733584 or standard chemotherapy. It uses a parallel group design with one group on the new drug and one on usual care, and only the independent reviewer of outcomes is blinded, with the main goal to see which treatment controls the cancer better.
The trial is listed as “Not yet recruiting,” with initial regulatory submission dated 12 Dec 2025, marking the formal start of the approval process to run the study. The latest update was posted on 18 Mar 2026, signaling that the protocol has been refreshed and that the program is active as GSK moves toward site activation and patient enrollment.
For investors, this update shows GSK pushing deeper into oncology with a late-stage asset that could strengthen long-term revenue if the data outperform standard chemotherapy. Success would support the company’s growth narrative versus peers in women’s cancers, while delays or weak results could weigh on sentiment and benefit competitors already selling ovarian cancer drugs.
The study remains in progress at the setup stage, with details and ongoing updates available on the ClinicalTrials.gov portal under NCT07286266.
To learn more about GSK’s potential, visit the GlaxoSmithKline drug pipeline page.
